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Supplementation with dairy calcium and/or
flaxseed fibers in conjunction with orlistat
augments fecal fat excretion without
altering ratings of gastrointestinal comfort
Mette Kristensen, Signe Rømer Juul, Karina Vejrum Sørensen, Janne Kunchel Lorenzen and Arne Astrup*
Abstract
Background: Orlistat is a lipase inhibitor which reduced absorption of dietary fat by ~30% thereby inducing a
weight loss; however, side effects occur as a consequence of increased colonic fat content. To test the hypothesis
that most gastrointestinal side events induced by treatment with orlistat could be prevented/ameliorated by
concomitant use of natural dietary components, flaxseed fiber (FF) and/or dairy calcium (Ca), binding liquid fats to
more solid complexes.
Methods: A randomized controlled dietary intervention study. Thirty-eight obese adults completed a 1-week run-in
period, where all participants were treated with orlistat (60 mg t.i.d) and were hereafter randomized to 12 weeks
dietary supplementation with/without 5 g FF (FF+/FF-) and/or 1200 mg dairy calcium (Ca+/Ca-) in conjunction with
orlistat. All feces were collected for 3 days, and diet was recorded for 5 days, during run-in and week 4. The primary
end-point, gastrointestinal symptoms, was assessed biweekly. At baseline and after 12 weeks, cardiometabolic risk
markers and anthropometrics were evaluated as secondary end-points.
Results: Both FF and Ca increased fecal fat excretion (P = 0.02 and P = 0.04, respectively). Although fecal fat
excretion increased by ~100% in the FF+/Ca + group, and only by ~12% in the FF-/Ca + group, no interaction
between FF and Ca was present, suggesting an additive effect. The fecal fat excretion was ~10 g/d higher with FF
and Ca (~25 g/d) compared to fecal fat excretion with orlistat alone (~15 g/d). Mean ratings of severity of diarrhea
tended to increase with Ca (P = 0.03) but not with FF. No other gastrointestinal symptoms, or a composite score of
symptoms, were affected by the dietary supplements. Body weight was reduced in all groups but did not differ
between groups, whereas waist circumference was most reduced in the FF+/Ca + group. No effects of dietary
supplements on cardiometabolic risk factors were observed, except a slight increase in diastolic blood pressure
(P = 0.03) with FF, but not Ca.
Conclusions: Our results do not support an improvement in orlistat-induced gastrointestinal side effects by
concomitant use of FF and Ca. However, fecal fat excretion was increased with both FF and Ca in the absence
of a worsening of symptoms, warranting further studies powered to detect potential additive weight loss effects.
Trial registration: Ethical Committee of the Capital Region of Denmark reg. no. H-1-2010-110, 02-11-2010 database
no. NCT01320228, 21-03-2011.
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Background
Orlistat is a gastrointestinal lipase inhibitor and thus re-
duces the extent of fat absorption from the diet. At the
recommended therapeutic dose (60–120 mg t.i.d.) and
in conjunction with dietary advice, orlistat produces a
negative energy balance which results in weight loss of
2.9 kg (95% CI: 2.5; 3.2) more than placebo [1]. Orlistat
inhibits absorption of dietary fat by ~30%; however, side
effects occur as a consequence of increased colonic fat
content. The most commonly reported side effects are
oily or fatty stools, oily discharge, fecal incontinence as
well as abdominal pain, nausea, vomiting, diarrhea and
rectal pain [2]. They are usually temporary; however,
most patients do not use orlistat long enough to ex-
perience a reduction in gastrointestinal symptoms as
also substantiated by the increased risk of discontinu-
ation when treated with orlistat compared to placebo
reported in a meta-analysis, where ~40% of dropouts
were related to gastrointestinal symptoms [3]. Thus,
in order to optimize the treatment of orlistat, ways to
curb the gastrointestinal side effects for orlistat are of
great interest.
With orlistat 120 mg t.i.d., the proportion of ingested
fat being excreted in stool have been found to be in-
creased from baseline levels of 6% to between 20 and
35%, with an estimated mean value of 30% [4]. With a
lower dosage of orlistat around 20% of the ingested fat is
daily excreted depending on body weight, degree of cal-
oric restriction and the proportion of fat in the diet [4].
We have previously found that increasing dietary cal-
cium intake from e.g. 500 to 2000 mg is sufficient to
bind 5–7 g of fat [5–7], and although a meta-analysis
was unable to find difference in magnitude of effect
whether calcium originated from dairy or other sources
[8], we recently found dairy calcium to result in a greater
fecal fat excretion compared to supplemental calcium,
and to better diminish postprandial chylomicron triacyl-
glycerol concentration [9], which is also indicative of an
interference with fat absorption. Although the mechan-
ism of action is not fully elucidated, it has been pro-
posed that calcium and lipids form insoluble soaps in
the intestine, and thus, an increased fecal fat content
resulting from increased calcium intake may not give
rise to gastrointestinal symptoms. Likewise, we have
found flaxseed fibers (FF) to inhibit fat absorption, even
when administered in small doses in humans [10–12], as
well as in an animal model [13], likely through a binding
and/or encapsulation of fat in the intestine [14]. Dietary
fibers, particularly those which form viscous solutions
when hydrated, may encapsulate fat in a more viscous
chyme, but in vitro studies have also suggested that diet-
ary fibers to bind directly to lipids and bile acids [15].
Thus, dietary fibers may also affect fecal fat excretion.
However, one previous study, in which interaction
between intake of dietary fat and fiber and orlistat was
investigated, fecal fat excretion was not altered by high
vs. low fiber diets [16]. However, accessibility of dietary
fat (intracellular vs. extracellular fat) did influence the
fat-blocking actions of orlistat. Further, Cavaliere et al.
[17] previously found that daily supplementation with
12–18 g of psyllium over 30 days reduced gastrointes-
tinal symptoms compared to placebo; however fecal fat
excretion was not investigated.
In addition to its effect on fat-absorption, flaxseed fi-
bers also suppress hunger [11, 18], and thus may aid
weight loss when given in conjunction with orlistat,
whereas the evidence for an effect of calcium on appetite
is more controversial [19].
Here, we test the hypothesis that supplementation
with flaxseed fibers and/or dairy calcium in the form of
Capolac® (Ca) will alleviate the gastrointestinal symp-
toms related to orlistat treatment. Furthermore, the
effects of dietary supplementation in conjunction with
orlistat on fecal parameters, dietary intake, anthropom-




The study was designed as a randomized controlled par-
allel intervention study of 13 weeks duration. For one
week (run-in), all participants received alli® (Orlistat,
60 mg t.i.d) and dietary counseling to facilitate a weight
loss. Hereafter participants were randomized in a 2 × 2
factorial design to supplementation with/without flax-
seed fibers and dairy calcium in addition to treatment
with alli® for another 12 weeks. Anthropometry, blood
pressure and gastrointestinal symptoms was assessed
every 2 weeks from run-in to week 12, fecal samples
were collected for 72 h during run-in (alli® only) and
during week 4 (alli® plus dietary supplements) concur-
rent with a 5d weighed food record. Fasting blood sam-
ples were drawn at time of randomization (week 0) and
at the end of the study (week 12). At each visit, other ad-
verse events were registered as part of an interview.
Randomization and allocation concealment
Randomization was done using a stratified block randomization
according to sex (M/F) and body mass index (BMI)
(BMI < 35 kg/m2 ≥ BMI). Within each of the four strata,
participants were randomized to supplementation with/
without Ca and FF, respectively, by block randomization
using web-based software (www.randomization.com) with
uneven sized blocks. The randomization list was created
by one of the research team prior to commencement of
the study (MK), and allocation of supplement group was
done by one of the research team (MK, SR, KVS) during
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the randomization visit (week 0), thus allocation was not
concealed.
Participants
Inclusion criteria were BMI between 30 and 40 kg/m2
and age between 20 and 60 years. Exclusion criteria
were: dairy allergy and/or intolerance, allergy to Orlistat,
infectious or metabolic diseases, gastrointestinal disor-
ders (previous and current), dietary supplement use
during the study and 1 month prior to the study, >1 y
postmenopausal (self-reported), pregnancy or lactation,
previous use of Orlistat, treatment with medication
known to interact with orlistat, dieting or weight change
>3 kg within 3 months prior to the study, and participa-
tion in other studies. Prescription medication was con-
sidered on an individual basis. All participants attended
a screening visit before enrolment, where weight, height,
waist circumference and blood pressure were measured.
Also, they were interviewed to assess eligibility for enrol-
ment. Here, they also filled in a Three Factor Eating
Questionnaire, in which each item scores either 0 or 1
point. The minimum score for factors I-II-III is therefore
0-0-0, the possible maximum score 21-16-14 [20].
Experimental diet
Weight loss program
The participants followed a slightly energy-restricted diet
based on their habitual choice of food items to aid
weight loss. The weight loss program was based on an
educational system, consisting of five color-coded iso-
energetic interchangeable units of 250 kJ representing dif-
ferent nutrients (protein-rich, complex carbohydrate-rich,
simple carbohydrate-rich, fat-rich and alcohol). The par-
ticipants were instructed to adhere to a diet of at least
−1250 kJ/d less than their estimated energy requirement
(ER) [21], but no less than 5000 kJ/d. To ensure an even
distribution of fat in the meals, the participants were
instructed to consume a minimum 20 g of fats with every
meal. Also, they were instructed to a minimum intake of
protein of 60 g/d to minimize loss of lean body mass. ER
was assessed based as follows: ER (kJ/d) = body weight ×
X + 4500), where X = 47 for women and 63 for men. The
participants met with a dietitian 4 times during the study,
and were instructed to keep a food diary which included
count of total units and number of color-coded units with
special emphasis on fat and protein in order to adhere to
the instructions provided.
Dietary supplements
The participant were instructed to take alli® (60 mg orlistat
t.i.d) in conjunction with their main meals for 13 weeks in
total. After a 1-week run-in period on alli®, the partici-
pants were randomized to supplementation with/without
flaxseed fibers and dairy calcium in addition to treatment
with alli®. The supplements were given three times daily
together with the main meals. The supplements were pro-
vided in small sachets as powders every two weeks, and
the participants were instructed to consume it either as
dissolved into a beverage or sprinkled on top of their
foods. The flaxseed fiber extract (Biogin biochemicals
co. Ltd, China) contained 70% of dietary fiber (primar-
ily soluble dietary fibers) and contributed 5 g of dietary
fiber/d. The dairy calcium extract (Capolac® MM-0525;
Arla Foods, Denmark) contained 25% Ca from milk and
a total of 1200 mg of Ca was provided daily. Whole-
grain rice flour served as a placebo and contributed
0.2 g of dietary fiber/d. The four different supplements
were marked as A, B, C and D. This was done by the
packaging company, and the supplement codes were
kept in a sealed envelope by a staff member not related
to the study until the study was finalized. Thus, both
participants and all study staff were blinded to the cod-
ing of the supplements.
As orlistat affects fat absorption, absorption of fat-
soluble vitamins may be diminished. Thus, all partici-
pants were provided with vitamin A (900 μg, 3000 iu), D
(10 μg); E (335 mg) and K (150 μg) for daily supplemen-
tation (Natur-Drogeriet, Hoerning, Denmark).
Compliance assessment
Compliance to both alli® and dietary supplements (not
fat-soluble vitamins) were assessed by counting returned
unused medication and dietary supplements at each visit.
Participants were considered compliant when at least
85% of the medication and dietary supplement, respect-
ively, were taken over the entire study period.
Anthropometric measures and blood pressure
All measurements were performed in the morning after
an overnight fast (>10 h) and abstention from alcohol
and physical exercise for 24 h. Body weight was mea-
sured on an electronic scale while the participants were
wearing light clothing and no shoes (Tanita BWB-600,
Japan). Height was measured to the nearest 0.5 cm by
using a wall-mounted stadiometer without shoes at the
first visit (Seca, Hultafors, Sweden). Waist circumfer-
ence was measured two times to the nearest 0.5 cm at
the narrowest point between the iliac crest and the low-
est rib after expiration using a non-flexible measuring
tape and the mean value calculated. Blood pressure
measurements on the same (dominant) arm at each
visit were performed in the upright sitting position after
10 min of rest with an automatically inflated cuff (UA-
787; A & D Co Ltd, Saitama, Japan). Two measure-
ments with at least one minute in between were
performed and the mean value calculated.
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Assessment of gastrointestinal symptoms
To assess gastrointestinal symptoms, visual analogue
scales were used. They are 100 mm in length with words
anchored at each end. These were used to asses both se-
verity (0 mm = ‘none’ and 100 mm = ‘very severe’) and
frequency (0 mm= ‘not more often than normal’ and
100 mm = ‘much more often than normal’) of 15 differ-
ent gastrointestinal symptoms. These symptoms were se-
lected based on known adverse events related to orlistat
treatment, and includes: oily stools, flatus with oily dis-
charge, fecal incontinence, fecal urgency, loose stools,
frequent stools, bloating, nausea/vomiting, rectal pain,
abdominal pain, stomach rumbling, flatus, oily spotting,
diarrhea and constipation. Gastrointestinal symptoms
were assessed at each visit. Furthermore, a composite
score of gastrointestinal symptoms most frequently (seen
in ≥1 in 10 according to the product leaflet) observed
for both severity and frequency was calculated as the
mean follows: ΣFrequency (oily stools; flatus; fecal urgency, fecal
incontinence, flatus with oily discharge, loose stools, abdominal pain,
diarrhea, frequent stools)/9 and ΣSeverity (oily stools; flatus; fecal
urgency, fecal incontinence, oily spotting, loose stools, abdominal pain,
diarrhea, frequent stools)/9.
Assessment of dietary intake
A food frequency questionnaire (FFQ) to estimate the
participants’ habitual Ca intake was filled in at baseline
[22]. Here, habitual fiber intake of the subjects was also
estimated using a FFQ, in which participants stated por-
tion size and frequency for their intake of fiber-rich food
items during the last month. The habitual daily dietary
fiber intake was estimated by using the average fiber
content of a range of products within each food item
category. The FFQ was validated in 125 individuals
against a 7-day weighed food record (Pearsons correl-
ation 0.63; P < 0.001) [23].
During the run-in period, the subjects completed a 5-
day weighed food record. This was done concurrent with
the fecal sample collection, as the 72 h of fecal samples
were collected during the last 3 days of food recording
allowing for estimation of relative excretion of fat and en-
ergy. All recorded foods and energy-containing beverages
were entered into the Dankost 3000 dietary assessment
software (Dankost 3000, version 2.5, Danish Catering
Center, Herlev, Denmark) and mean total intake of energy,
fat, carbohydrates, protein and total dietary fiber was
calculated for each 5-day registration period.
Laboratory procedures
Blood samples
Fasting blood samples were collected at randomization
(week 0) at the end of the study (week 12) after an over-
night fast (>10 h) and abstention from alcohol and phys-
ical exercise for 24 h. Samples were stored at −20 °C
until analyses. Plasma concentrations of glucose and
serum concentrations of triacylglycerol, total, HDL and
LDL cholesterol and insulin were measured as described
elsewhere [11]. HOMA index of insulin resistance
(HOMA-IR) was calculated as (fasting glucose (mmol/
L) × fasting insulin (mU/L))/22.5. Hemoglobin A1C
(HbA1c) was measured by using an immunoturbidi-
metric assay with a Unimate HbA1C test kit (Roche
Diagnostics) on a COBAS MIRA Plus chemistry analyzer
(Roche Diagnostic Systems Inc). Serum high sensitivity
CRP (hsCRP) was measured by a solid-phase chemilu-
minescent immunometric assay using an IMMULITE®
1000 Automated Immunuassay Analyzer. All samples
were analyzed in one batch after the study was com-
pleted and all CV% were <5%.
Fecal samples
All fecal samples were collected in pre-weighed plastic
containers for 72 h during run-in (alli® only) and during
week 4 of the intervention period (alli® plus dietary sup-
plements). Participants kept the plastic containers in a
cooled box and brought them to the department daily.
Samples were weighed and freeze-dried, homogenized
and samples from each participant’s 72 h collection were
pooled. Fecal energy excretion was determined using
bomb calorimetry (IKA- calorimeter system 4000,
Heitersheim, Germany). Samples were hydrolyzed with
3 N hydrochloric acid before total fat content was mea-
sured by acidic Bligh & Dyer extraction [24]. The appar-
ent digestibility of fat was calculated relative to intake as
100 ×mean fat excreted (g/d)/mean intake of fat (g/d).
Statistical analyzes
The study was a pilot study, exploratory in nature and
thus no power calculation has been made. A total of 72
participants was intended to be randomized to the four
treatment groups in a balanced design (n = 18). As side
effects are expected to occur in 20–25% of the partici-
pants on treatment with alli®, it is expected that a
decrease in side effect frequency and severity was detect-
able when summarizing the reported side effects.
All statistical analyses and calculations were per-
formed using the Statistical Analysis System software
package, version 9.3 (SAS Institute Inc., Cary, NC,
USA). All dependent variables were controlled for
homogeneity of variance and normal distribution by
investigation of residual plots and normal probability
plots. A one-way ANOVA was used to compare base-
line values between groups.
An ANCOVA was used to investigate the effect of
dietary supplementation on all parameters. Participant
was included as a random variable, age and correspond-
ing baseline value were modeled as covariates and FF,
Ca, their interaction (FF × Ca) and sex were modeled as
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fixed variables. The FF × Ca interaction was only omit-
ted, when P > 0.10. Posthoc pairwise comparisons be-
tween dietary supplements were made when the FF × Ca
interaction was significant; otherwise main effects of FF
and Ca are reported. All analyses were completed as
completers only (CO), as efficacy was the primary focus
of the present study. Results are presented as means ±
SEM or as median (95% CI) when appropriate and the
statistical significance level was defined as P < 0.05.
Results
A total of 69 overweight and obese adults were screened
for eligibility following advertising in the local papers in
the Copenhagen area and pre-screening via telephone
from April 2011 to January 2012. Of these, 59 were en-
rolled in the study, 57 were randomized after the run-in
period, and a total of 38 completed the study (Fig. 1).
We aimed at enrolling 72 participants; however, diffi-
culty with recruitment resulted in a smaller sample size
than initially anticipated. In total, 6 participants dropped
out due to the side effects of alli® treatment, of which 1
dropped out during the run-in period, i.e. before
randomization. The remaining dropouts appeared to be
unrelated to the dietary intervention. There was no
difference between groups in baseline characteristics
(Table 1).
During the study period, four participants suffered
from illness which required antibiotic treatment (1 in
FF-/Ca-; 2 in FF+/Ca-; 1 in FF-/Ca+). Adverse events
not directly related to the gastrointestinal tract, such as
headache was reported in 2, 3, 2 and 4 participants in
the FF-/Ca-, FF+/Ca-, FF-/Ca + and FF+/Ca + groups, re-
spectively and dizziness was reported in one participant
in each of the FF-/Ca + and FF+/Ca- groups. Other ad-
verse events reported included only normal illness, such
as common cold, back pain, sinus infection and tooth
ache, which was not a plausible side effect of the dietary
supplements or alli®.
Compliance and dietary intake
Generally, the compliance to the dietary supplements
over the entire study was good (FF-/Ca-: 81.8 ± 12.8%;
FF+/Ca-: 84.5 ± 12.9%; FF-/Ca+: 89.6 ± 11.2%; FF+/Ca+:
89.2 ± 4.5%). There was a tendency towards an increased
compliance for Ca + vs. Ca- (P = 0.09), whereas compli-
ance did not differ for FF+ vs. FF- (P = 0.66). In total, 8
of the 38 participants completing the study had a mean
compliance below 85%. Compliance with alli® treatment
was better than for dietary supplement compliance (FF-/
Ca-: 95.0 ± 15.7%; FF+/Ca-: 95.9 ± 7.3%; FF-/Ca+: 99.0 ±
5.8%; FF+/Ca+: 97.7 ± 8.7%), but did not differ between
groups. Only one participant had a mean compliance
Fig. 1 Flow diagram: Parallel intervention study with orlistat treatment plus placebo supplement (FF-/Ca-) or flaxseed fibers (FF), and/or dairy Ca
(Ca) supplements as part of an energy-restricted diet. The diagram includes detailed information about the study
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below 85% of alli®. Participants reported that non-
compliance most often occurred in the morning. Com-
pliance with the dietary supplements and alli® exhibited
a weak, although significant correlation (Pearson’s cor-
relation coefficient R = 0.39; P = 0.016).
There was no difference between groups at baseline in
total energy intake, absolute fat intake or dietary macro-
nutrient composition (Additional file 1: Table S1). As
intended, the energy contribution from fat was high,
ranging from 32.9 ± 1.6E% to 39.2 ± 3.2E% at baseline.
There was no change in dietary intake over the course
of the study in either group.
Gastrointestinal symptoms
Baseline ratings of frequency and severity of gastrointes-
tinal symptoms did not differ between groups, except for
severity ad frequency of abdominal pain (Additional file 1:
Tables S2 and S3). No effect of FF or Ca on neither sever-
ity or frequency of the composite score was observed
(Fig. 2). Also, none of the individual gastrointestinal
symptoms measured were affected by FF and Ca sup-
plementation, except for severity of diarrhea, for
which an interaction between FF and Ca tended to be
present (P = 0.082). Posthoc analyses showed a ~6 fold
increase in severity of diarrhea after combined supple-
mentation of FF and Ca (FF+/Ca+) compared with
baseline, which differed from the group only supple-
mented with FF (FF+/Ca-) (P = 0.03), thus an effect of
Ca only seen with concomitant FF supplementation.
For most gastrointestinal symptoms reported, both se-
verity and frequency of symptoms decreased with
time. Finally, dietary supplementation did not affect
rating of the symptoms less commonly reported with
alli® treatment (data not shown).
Fecal parameters
In total, complete fecal collections during week 4 were re-
ceived from 39 participants. None of the fecal parameters
differed between treatment groups at baseline (P > 0.30)
(Table 2). Supplementation with FF, but not Ca, tended to
increase the number of defecations (P = 0.07). This ef-
fect was attenuated after adjustment for compliance
(P = 0.096), which may be explained by a positive cor-
relation between defecation frequency and compliance
(R = 0.47; P = 0.003). Fecal wet weight increased with
supplementation of Ca (P = 0.04), and tended also to
increase with FF (P = 0.09); however % DM was un-
affected by both Ca and FF. Both FF and Ca supplementa-
tion increased fecal fat excretion (P = 0.02 and P = 0.04,
respectively). Although fecal fat excretion increased by
~100% in the FF+/Ca + group, but only by ~12% in the
FF-/Ca + group (Table 2, Fig. 3), no interaction between
FF and Ca was observed (P = 0.65). When expressed rela-
tive to food intake, the proportion of fat excreted tended
to increase with both FF and Ca (P = 0.08 and P = 0.07,
respectively).
Anthropometric and cardiometabolic risk markers
There was no difference between groups in baseline
values, except for HbA1c (P = 0.03) (Table 3). Participants
in all four groups experienced a weight loss (P < 0.01)
which was also accompanied by decreased BMI and waist
circumference in all groups (P < 0.01). An interaction be-
tween FF and Ca with respect to waist circumference was
seen (P = 0.03), as waist circumference tended to decrease
more with the combined supplementation of FF and Ca
(−5.8 cm) compared to either FF (−3.8 cm) or Ca
(−2.7com) alone, but did not differ from control (FF-/Ca-)
(−6.1 cm). Systolic blood pressure was not affected by ei-
ther dietary supplement, whereas diastolic blood pressure
was slightly increased with FF supplementation (P = 0.03).
Blood lipids were unaffected by dietary supplementa-
tion, as were markers of glucose homeostasis (glucose,
insulin, HOMA-IR and HbA1c). Finally, FF, but not Ca,
resulted in increased hsCRP concentrations (P = 0.03).
When a cut-off value of 10 pg/mL was applied to
Table 1 Characteristics of the participants at randomization
FF- FF+
Ca- (n = 11) Ca + (n = 15) Ca- (n = 15) Ca + (n = 16)
Age (y)
Females/males (n) 9/2 13/2 12/3 12/4
Smokers (%) 36 40 33 38
Habitual Ca intake (mg/d) 1196 ± 533 1106 ± 517 832 ± 413 1084 ± 742
Habitual DF intake (g/d) 23.6 ± 10.3 26.2 ± 11.2 21.5 ± 6.4 22.2 ± 13.1
TFEQ:
Cognitive dietary restraint score 7.5 ± 3.4 9.2 ± 4.2 9.4 ± 3.4 8.9 ± 3.8
Dis-inhibition score 11.0 ± 3.1 9.4 ± 3.3 9.8 ± 4.3 8.1 ± 2.7
Susceptibility to hunger score 8.7 ± 3.2 7.9 ± 3.7 8.0 ± 3.9 6.5 ± 3.8
Abbreviations: DF dietary fiber, TFEQ three factor eating questionnaire
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exclude participants with potential acute infections, the
effect of FF was however attenuated (n = 31, P = 0.21)
(data not shown).
Discussion
We tested the hypothesis that supplementation with FF
and/or Ca would alleviate orlistat-induced gastrointes-
tinal symptoms as a consequence of intestinal sequester-
ing of free oil, possibly also accompanied by increased
fecal fat excretion. We were not able to demonstrate an
improvement in gastrointestinal symptom profile; but
interestingly, we found that combined supplementation
of FF and Ca resulted in a marked increase in fecal fat
excretion compared to control (FF-/Ca-), which was
not observed with either FF or Ca alone. Thus, a
combined supplementation of FF and Ca may aid
weight loss as a consequence of fecal fat losses be-
yond the effect of orlistat.
The increased fecal fat excretion with both FF and Ca,
and in particular the combination of the two, was not
Fig. 2 Composite score for gastrointestinal symptoms. Mean frequency and severity of composite score of 9 gastrointestinal symptoms (oily
stools; flatus; fecal urgency, fecal incontinence, flatus with oily discharge, loose stools, abdominal pain, diarrhea, frequent stools) during the
12 weeks intervention with orlistat plus placebo (FF-/Ca-) or flaxseed fibers (FF) and/or dairy Ca (Ca) supplements. The lower the score the less
frequent or severe the symptom
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accompanied by changes in ratings of gastrointestinal
symptoms apart from a tendency towards an increase in
severity, but not frequency, of diarrhea with Ca. The
fecal fat excretion was ~10 g/d higher with FF and Ca
(~25 g/d) compared to fecal fat excretion with orlistat
alone (~15 g/d). which is a marked increase from the
~155 g/d of fecal fat excretion with orlistat alone.
Orlistat diminishes fat absorption by inhibiting the activ-
ity of the gastrointestinal lipase resulting in an increased
amount of intact non-hydrolyzed triacylglycerols in the
intestine. Ca is proposed to form insoluble soaps with
these triacylglycerols [25], which may occur more dis-
tally, thus, orlistat may not affect the ability of Ca to
form soaps, but rather result in an increased amount of
lipids available for soap formation. FF are highly viscous
dietary fibers [26] and as such, they are proposed to in-
crease the viscosity of the intestinal contents which both
thickens the unstirred water-layer along the mucosal
barrier as well as slows digestive enzyme activity, includ-
ing lipases [14]. Thus, both mechanisms of action appear
to act in combination with orlistat, which does not ap-
pear to affect magnitude of effect of the supplements.
Orlistat alone resulted in a fecal fat excretion of 25-30%
of intake, and fecal fat excretion depends on dose of orli-
stat, although not in a linear manner [4]. Thus, compo-
nents exerting their effects via different mechanisms
may exceed this plateauing at a given dose, as suggested
by our results. However, the combination of FF and Ca
without orlistat treatment has not been tested; thus it is
unknown whether orlistat may in fact facilitate some of
the effects observed by increasing the intestinal triacyl-
glycerol content.
As previously reported, attrition rates are high for orli-
stat treatment [3], and the present study was no excep-
tion. Overall, 33% of the participants dropped out of the




Ca- (n = 6) Ca + (n = 13) Ca- (n = 10) Ca + (n = 10) Baseline FF Ca
Defecation frequency (n/d)
Baseline 1.43 ± 0.17 1.78 ± 0.32 1.21 ± 0.15 1.21 ± 0.11 0.50 0.07 0.79
Week 4 1.24 ± 0.14 1.47 ± 0.26 1.24 ± 0.10 1.39 ± 0.18
Fecal wet weight (g/d)
Baseline 169.8 ± 45.9 184.9 ± 31.2 141.5 ± 35.6 152.4 ± 35.6 0.81 0.09 0.04*
Week 4 129.5 ± 36.5 187.1 ± 24.8 144.7 ± 28.3 199.6 ± 28.3
Fecal dry matter (%)
Baseline 27.6 ± 2.2 28.7 ± 1.4 30.9 ± 1.5 30.8 ± 1.8 0.56 0.78 0.54
Week 4 29.8 ± 1.8 29.0 ± 1.2 30.5 ± 1.1 30.3 ± 1.7
Fecal fat excretion (g/d)
Baseline 17.7 ± 3.2 18.6 ± 2.2 18.6 ± 2.5 15.3 ± 2.5 0.75 0.02* 0.04*
Week 4 15.4 ± 4.3 20.8 ± 2.9 21.0 ± 3.3 25.6 ± 3.3
Fecal fat excretion (%)
Baseline 24.5 ± 6.3 31.7 ± 4.3 32.1 ± 4.9 24.9 ± 3.8 0.38 0.08 0.07
Week 4 24.1 ± 10.3 37.1 ± 7.0 36.0 ± 8.0 48.1 ± 8.0
*n = 39; completers only population
**P-values refer to an ANCOVA model with adjustment for baseline value, sex and age
Fig. 3 Fecal fat excretion. Individual and mean change in fecal fat
excretion (g/d) from baseline (orlistat treatment only) to week 4 (orlistat
plus placebo (FF-/Ca-) or flaxseed fibers (FF) and/or dairy Ca (Ca)
supplements). * Indicate a significant effect of Ca (p= 0.02) and # indicate
a significant effect of FF (p= 0.04) compared to control in an ANCOVA
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study, and ~40% (6 participants of which 5 dropped out
after randomization) of these were directly related to
gastrointestinal side effects. Only one participant receiv-
ing Ca dropped out, whereas three participants receiving
FF dropped out indicating that the supplements affected
gastrointestinal symptoms differently; however the study
was too small to assess differences in attrition rates and
thus this warrants further investigations. Nonetheless,
the compliance to alli® was very high, which may be
related to the fact that a few participants consumed a
larger amount of alli® than instructed, likely because they
know that a higher dose of orlistat could be taken with-
out increased risk. The compliance to the dietary supple-
ments was lower, likely due to its effect on palatability of
the foods in which they were applied. However, a large
proportion of the drop outs occurred during week 4,
where dietary records and fecal collections took place.
Thus, some of the dropouts may be related to the cum-
bersome procedures the participants were requested to
follow, rather than the intervention itself.
Surprisingly, FF supplementation resulted in increased
diastolic blood pressure and hsCRP, which is in contrast
to previous reports on anti-inflammatory effects of flax-
seeds among obese individual [26, 27]. Mean baseline
blood pressure was within the normal range in the current
study, whereas mean hsCRP concentrations were very
high indicating an at risk population. However, in the sub-
set of participants with hsCRP < 10 pg/mL, the effect was
Table 3 Cardiometabolic risk markers before and after 12 weeks supplementation with flaxseed fibers (FF) and/or dairy calcium (Ca)
in addition to alli®*
P-values**
FF- FF+ Intervention
Ca- (n = 6) Ca + (n = 12) Ca- (n = 10) Ca + (n = 10) Baseline FF Ca
Body weight (kg) Baseline 98.9 ± 8.4 103.4 ± 5.2 91.2 ± 3.9 95.6 ± 2.8 0.30
Week 12 94.0 ± 9.9 98.9 ± 4.9 87.4 ± 3.8 91.4 ± 2.4 0.46 0.80
WC (cm) Baseline 111.0 ± 4.8 111.3 ± 3.4 104.5 ± 2.6 104.2 ± 3.2 0.56
Week 12 104.9 ± 6.3ab 107.5 ± 3.2a 101.8 ± 2.7a 98.4 ± 2.9b FF × Ca: 0.03*
Systolic BP (mmHg) Baseline 116 ± 6 118 ± 2 113 ± 2 123 ± 4 0.52
Week 12 116 ± 5 114 ± 3 115 ± 3 129 ± 5 0.58 0.70
Diastolic BP (mmHg) Baseline 82 ± 3 81 ± 3 78 ± 2 84 ± 2 0.23
Week 12 80 ± 4 79 ± 2 75 ± 3 84 ± 2 0.03* 0.61
TAG (mmol/L) Baseline 0.85 ± 0.33 1.46 ± 0.23 1.65 ± 0.25 0.99 ± 0.25 0.15
Week 12 0.85 ± 0.18 1.27 ± 0.14 1.17 ± 0.14 0.92 ± 0.14 0.42 0.56
T-C (mmol/L) Baseline 4.87 ± 0.39 5.29 ± 0.28 5.31 ± 0.30 5.62 ± 0.30 0.52
Week 12 2.39 ± 0.38 4.94 ± 0.27 4.95 ± 0.30 5.11 ± 0.30 0.95 0.87
LDL-C (mmol/L) Baseline 2.94 ± 0.33 3.24 ± 0.24 3.31 ± 0.26 3.28 ± 0.26 0.82
Week 12 2.52 ± 0.30 3.09 ± 0.21 3.12 ± 0.24 2.98 ± 0.24 0.98 0.62
HDL-C (mmol/L) Baseline 1.45 ± 0.10 1.30 ± 0.07 1.18 ± 0.06 1.65 ± 0.09 0.17
Week 12 1.35 ± 0.15 1.15 ± 0.05 1.18 ± 0.06 1.52 ± 0.08 0.19 0.81
Glucose (mmol/L) Baseline 5.38 ± 0.19 5.34 ± 0.13 5.24 ± 0.15 5.42 ± 0.15 0.84
Week 12 5.29 ± 0.20 5.34 ± 0.14 5.30 ± 0.16 5.19 ± 0.16 0.40 0.32
Insulin (pmol/L) Baseline 83.9 ± 26.6 103.3 ± 18.8 102.4 ± 20.6 73.4 ± 20.6 0.67
Week 12 62.0 ± 38.3 114.6 ± 24.7 83.0 ± 27.1 70.0 ± 27.1 0.52 0.25
HOMA-IR Baseline 2.92 ± 0.58 3.54 ± 0.63 3.65 ± 1.21 2.59 ± 0.41 0.68
Week 12 2.10 ± 0.46 3.99 ± 1.31 2.96 ± 0.80 2.34 ± 0.47 0.97 0.67
HbA1c (%) Baseline 5.32 ± 0.05a 5.59 ± 0.08b 5.50 ± 0.09ab 5.57 ± 0.12b 0.03*
Week 12 5.38 ± 0.10 5.48 ± 0.08 5.48 ± 0.09 5.47 ± 0.10
hsCRP (pg/mL) Baseline 3.23 ± 1.76 3.11 ± 1.15 4.81 ± 1.43 7.61 ± 2.41 0.92
Week 12 3.93 ± 0.70 2.07 ± 0.45 5.06 ± 1.61 5.80 ± 1.90 0.03* 0.61
Abbreviations: BMI body mass index, BP blood pressure, HDL-C HDL cholesterol, hsCRP high sensitivity C-reactive protein, HOMA-IR Homeostasis Model of
Assessment - Insulin Resistance, HbA1c glycated hemoglobin, LDL-C LDL cholesterol, TAG triacylglycerol, T-C total cholesterol, WC waist circumference
*n = 39; completers only population
**P-values refer to an ANCOVA model with adjustment for baseline value, sex and age. Columns with different superscript letters are significantly different; P<0.05
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attenuated; thus the pro-inflammatory effect of FF is not a
robust finding. Moreover, we conducted multiple compar-
isons i.e. the secondary end-points without adjustments,
which makes it likely that these findings are spurious and
a matter of chance. The findings need to be replicated in
independent studies.
Overall, compliance with both orlistat and dietary sup-
plements was good, but tended to be best with Ca,
whereas larger variations were observed in the FF supple-
mented groups. FF are viscous dietary fibers, and form
highly viscous solutions immediately upon hydration.
Thus the distribution of the FF as powders to be dissolved
in liquids or sprayed on foods, e.g. yoghurt, may have
given rise to less palatable foods, which may have affected
compliance. This is not the case for Ca, which is solubi-
lized and affects the taste of the food, but not the texture
and thus it may have been better tolerated.
Few studies have examined the effect of dietary com-
ponents on orlistat-induced fecal fat excretion and
gastrointestinal symptoms. In contrast to the current
findings, 6 g of psyllium given three times daily in con-
junction with 120 mg orlistat was found to decrease oc-
currence of gastrointestinal events compared to placebo
in a crossover study in 30 obese participants; however,
fecal fat excretion was not assessed [17]. Psyllium and
FF are both highly viscous dietary fibers, but the dose of
psyllium was ~3 times higher than the FF dose used in
the present study, which may explain why the results
differ. Furthermore, a crossover design may be prefera-
ble when assessing subjective ratings of symptoms as
inter-individual variation then can be eliminated. In the
present study, we were not able to control type of fat;
however, amount of fat consumed did not differ between
groups and only decreased by few grams during the
study, thus we do not believe fat intake to have affected
our results, where patterns of relative fecal fat excretion
(% of intake) followed that of fecal fat excretion in abso-
lute amounts. A highly controlled study revealed that
foods high in dietary fibers given in conjunction with
3 × 80 mg orlistat did not affect fecal fat excretion pat-
terns differently than low-fiber foods, whereas extracel-
lular fat (rendered lard) increased fecal fat excretion
compared to intracellular fat (un-rendered lard) [16].
These results suggest that fat type in the background
diet may be of great importance for the efficacy of orli-
stat whereas the content of dietary fibers, in natural food
matrices, may vary considerably without affecting fat
absorption.
Major strengths of the present study are the 2x2
factorial design, which enabled us to study interactions;
that the intervention was well-controlled and resulted in
a high compliance in all participants; and that that both
gastrointestinal symptoms and fecal fat excretion were
assessed and could thus be compared. However, the
small sample size, partly caused by a large attrition rate,
limits our ability to make firm conclusions based on
these results.
Conclusions
The present findings do not support alleviation of orlistat-
induced gastrointestinal side effects by supplementation
of FF and/or Ca as hypothesized. However, fecal fat excre-
tion was increased with both FF and Ca in the absence of
a worsening of symptoms and to the greatest extent when
both FF and Ca were consumed indicating a substantial
additive effect.
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